Find drug development pipeline and deal Updates information

Lead Product(s): PF-05251749

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Biogen

Deal Size: $710.0 million Upfront Cash: $75.0 million

Deal Type: Acquisition January 13, 2020

Details:

With this purchase, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder in Parkinson’s disease.

Lead Product(s): VX-961

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 31, 2020

Details:

The NaV1.8 inhibitor did not meet the desired pharmacokinetic and tolerability profile which led to the dumping of the drug and detail plans to move a follow-up product to the clinic.

Lead Product(s): SBT-272

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2020

Details:

Second Generation Mitochondrial Targeted Candidate Enters Clinic with Potential to Treat Neurodegenerative Diseases.

Lead Product(s): Dextroamphetamine

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 21, 2020

Details:

Company to begin enrolling phase 1 clinical trial for first immune tolerance product, KAN-101, in first quarter of 2020.

Lead Product(s): KLS-13019

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 14, 2020

Details:

In comparison with CBD and morphine, KLS-13019 stood out as a viable drug candidate that out-performed CBD and poses as a viable alternative to the use of opioids.

Lead Product(s): DNL201

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 14, 2020

Details:

Phase 1b results with DNL201 in patients with Parkinson’s disease met all biomarker goals by demonstrating greater than 50% inhibition of pS935 LRRK2 and pRAB10 in blood for both doses tested.

Lead Product(s): N-Desethyloxybutynin

Therapeutic Area: Neurology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 13, 2020

Details:

New chemical entity and selective muscarinic receptor antagonist targeting large unmet need for a new treatment that can meaningfully improve the lives of patients with neurological conditions.